Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

BACKGROUND: Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients. METHODS: In this single-center retrospective analysis, we investigated the CD73 enzyme activity in patients with metastatic melanoma...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Transl Med
Huvudupphovsmän: Morello, Silvana, Capone, Mariaelena, Sorrentino, Claudia, Giannarelli, Diana, Madonna, Gabriele, Mallardo, Domenico, Grimaldi, Antonio M., Pinto, Aldo, Ascierto, Paolo Antonio
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2017
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5716054/
https://ncbi.nlm.nih.gov/pubmed/29202855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-017-1348-8
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk